{
    "nctId": "NCT00272740",
    "briefTitle": "SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex\u00ae After Aromatase Inhibitor Failure in Advanced Breast Cancer",
    "officialTitle": "An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex\u00ae (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 93,
    "primaryOutcomeMeasure": "Clinical Benefit Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological/cytological confirmation of breast cancer\n* progression under treatment with an aromatase inhibitor\n* At least one measurable or non-measurable lesion\n\nExclusion Criteria:\n\n* Prior treatment for breast cancer with more than 2 different hormonal agents\n* More than 1 chemotherapy for advanced disease\n* Presence of life-threatening metastatic visceral disease",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}